SCHEMBL2487933

SCHEMBL2487933

CCC(=C(CC)c1ccc(CN(C)C)c(O)c1)c1ccc(CN(C)C)c(O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.56
ALDH1A1 P00352 5/20 0.53
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
MAPT P10636 3/20 0.53
POLB P06746 3/20 0.53
KDM4E B2RXH2 2/20 0.53
THRB P10828 2/20 0.53
HKDC1 Q2TB90 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
GAA P10253 1/20 0.53
G6PD P11413 1/20 0.53
PABPC1 P11940 1/20 0.53
ALOX15 P16050 3/20 0.44
MAPK1 P28482 3/20 0.44
CYP2C19 P33261 3/20 0.44
CYP2C9 P11712 2/20 0.44
HSD17B10 Q99714 2/20 0.44
NR1I2 O75469 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2487931 1.00 JAK2 (0.56) JAK2ALDH1A1MEN1KMT2AMAPT
SCHEMBL2488426 0.87 JAK2 (0.72) JAK2ALDH1A1MEN1KMT2AMAPT
SCHEMBL13339124 0.87 JAK2 (0.72) JAK2ALDH1A1MEN1KMT2AMAPT
SCHEMBL2488427 0.87 JAK2 (0.72) JAK2ALDH1A1MEN1KMT2AMAPT
SCHEMBL2485475 0.84 JAK2 (0.78) JAK2ALDH1A1MEN1KMT2AMAPT
SCHEMBL2485483 0.84 JAK2 (0.78) JAK2ALDH1A1MEN1KMT2AMAPT
SCHEMBL2487256 0.81 ALDH1A1 (0.57) ALDH1A1MEN1KMT2AMAPTPOLB
SCHEMBL2487260 0.81 ALDH1A1 (0.57) ALDH1A1MEN1KMT2AMAPTPOLB
SCHEMBL13338341 0.81 ALDH1A1 (0.57) ALDH1A1MEN1KMT2AMAPTPOLB
SCHEMBL2485165 0.81 JAK2 (0.51) JAK2ALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013019655-A2 VIMENTIN AS A BIOMARKER FOR THE PROGRESSION OF MYELOPROLIFERATIVE NEOPLASMS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) 2013-02-07 WO claimed
US-20110301159-A1 KINASE INHIBITOR COMPOUNDS UNIVERSITY OF SOUTH FLORIDA (US) 2011-12-08 US claimed
EP-2376425-A2 KINASE INHIBITOR COMPOUNDS University of Florida Research Foundation, Inc. (US) 2011-10-19 EP claimed
WO-2010068710-A2 KINASE INHIBITOR COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2010-06-17 WO claimed
US-20140248634-A1 VIMENTIN AS A BIOMARKER FOR THE PROGRESSION OF MYELOPROLIFERATIVE NEOPLASMS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) 2014-09-04 US disclosed
WO-2013019655-A2 VIMENTIN AS A BIOMARKER FOR THE PROGRESSION OF MYELOPROLIFERATIVE NEOPLASMS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) 2013-02-07 WO disclosed
US-20110301159-A1 KINASE INHIBITOR COMPOUNDS UNIVERSITY OF SOUTH FLORIDA (US) 2011-12-08 US disclosed
EP-2376425-A2 KINASE INHIBITOR COMPOUNDS University of Florida Research Foundation, Inc. (US) 2011-10-19 EP disclosed
WO-2010068710-A2 KINASE INHIBITOR COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301159-A1 KINASE INHIBITOR COMPOUNDS JAK2, JAK1, JAK3 JAK2 1/4885ALDH1A1 3784/4885MEN1 2998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.